Gilead Sciences Inc
NASDAQ:GILD
Gilead Sciences Inc
NASDAQ:GILD
Price:
67.01 USD
-0.95%
Market Closed
Updated:
May 16, 2024
Gilead Sciences Inc
Income from Continuing Operations
|
Gilead Sciences Inc
Income from Continuing Operations Peer Comparison
Comparables:
ABBV
AMGN
MRNA
VRTX
REGN
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$456m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Income from Continuing Operations
-$6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-68%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Gilead Sciences Inc's Income from Continuing Operations?
Income from Continuing Operations
456m
USD
456m
USD
Based on the financial report for Mar 31, 2024, Gilead Sciences Inc's Income from Continuing Operations amounts to 456m USD.
What is Gilead Sciences Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-21%
-21%
Over the last year, the Income from Continuing Operations growth was -92%. The average annual Income from Continuing Operations growth rates for Gilead Sciences Inc have been 19% over the past three years , -40% over the past five years , and -21% over the past ten years .
You don't have any saved screeners yet
